🌐 WorldLive
Accueil › 🇦🇺 Australie › Science

Italfarmaco and JCR Pharmaceuticals Enter into Exclusive License Agreement for the Development and Potential Commercialization of Novel Investigational Therapy for Hunter Syndrome in the United States, Europe, and Latin America

📅 02/10/2026 06:30 📰 businesswire 👁️ 2 lectures 🌍 Australie 📂 Science
Italfarmaco and JCR Pharmaceuticals Enter into Exclusive License Agreement for the Development and Potential Commercialization of Novel Investigational Therapy for Hunter Syndrome in the United States, Europe, and Latin America

MILAN & HYOGO, Japan--(BUSINESS WIRE)--Italfarmaco and JCR announced an exclusive license agreement to develop and commercialize JR-141 in the United States, Europe, and Latin America.